Company / Financials
Orchestra BioMed Holdings, Inc. Financials
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$2.6M
FY2025 · -4.4% YoY
Net Income
-$61.0M
FY2025 · -24.2% YoY
Profit Margin
-2313.3%
FY2025 · net income / revenue
ROE
-185.2%
FY2025 · return on equity
Total Assets
$114.9M
FY2025
Total Debt
-
FY2025
Equity
$33.0M
FY2025
ROA
-53.1%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score -0.98 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$2.6M-4.4% YoYNet Income HistoryProfit after all expenses and taxes-$61.0M-24.2% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$204.0K+9.7% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$64.3M-24.8% YoYSG&A Expense HistorySelling, general, and administrative expenses$23.9M+18.1% YoYR&D Expense HistoryResearch and development spending$42.8M+26.6% YoYInterest Expense HistoryCost of borrowing and debt obligations-Income Tax HistoryTotal income tax expense$0EPS (Basic) HistoryBasic earnings per share-$1.66-12.2% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$1.66-12.2% YoY